n.a. (DSCI)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)
Derma Sciences To Present At The Rodman & Renshaw 13th Annual Global Investment Conference

Derma Sciences To Present At The Rodman & Renshaw 13th Annual Global Investment Conference

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced that the company will be participating in the Rodman & Renshaw 13th Annual Global...

11 Biotech Stocks Loved or Hated by Hedge Funds

11 Biotech Stocks Loved or Hated by Hedge Funds

A list of biotech stocks that saw signficant buying and selling from hedge funds in the second quarter.

Derma Sciences Reports Second Quarter Operating Results

Derma Sciences Reports Second Quarter Operating Results

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three and six months ended June 30, 2011.

Derma Sciences To Hold Second Quarter Financial Results Conference Call On August 16

Derma Sciences To Hold Second Quarter Financial Results Conference Call On August 16

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care announced today that the Company will hold a conference call on August 16, 2011 to discuss the financial ...

Derma Sciences Achieves Key MEDIHONEY® Sales Milestone

Derma Sciences Achieves Key MEDIHONEY® Sales Milestone

Derma Sciences, Inc. (“Derma Sciences” or “the Company”) (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced it has achieved a key...

Derma Sciences Launches Wound Treatment Video Series On ELearning Portal

Derma Sciences Launches Wound Treatment Video Series On ELearning Portal

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announces the launch of a new video series library within the Company’s eLearning Portal website.

Derma Sciences Receives FDA Clearance For MEDIHONEY® Hydrogel

Derma Sciences Receives FDA Clearance For MEDIHONEY® Hydrogel

Derma Sciences, Inc. (“Derma Sciences” or “the Company”) (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced it has received U.

Biotech Stock Mailbag: Ranking Cheap Biotechs

Biotech Stock Mailbag: Ranking Cheap Biotechs

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

10 Cheap Biotech Stocks That Could Soar

10 Cheap Biotech Stocks That Could Soar

These high-risk, high-reward biotech stocks have the potential for big gains if they can overcome significant challenges.

Derma Sciences Closes $29 Million Private Placement Financing

Derma Sciences Closes $29 Million Private Placement Financing

Derma Sciences, Inc. (“Derma Sciences” or “the Company”) (Nasdaq:DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced it has closed its previously...

Derma Sciences Raises $29 Million In Private Placement Financing

Derma Sciences Raises $29 Million In Private Placement Financing

Derma Sciences, Inc. (“Derma Sciences” or “the Company”) (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced it has entered into definitive...

Insiders Trading NS, TZOO, DSCI, CRR

Insiders Trading NS, TZOO, DSCI, CRR

The top 10 open-market insider purchases and sales filed at the SEC Friday.

Biotech Stock Mailbag: Fibrocell Science

Biotech Stock Mailbag: Fibrocell Science

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

Derma Stock Soars (DSCI)

Derma Stock Soars (DSCI)

Shares of Derma (Nasdaq:DSCI) have taken a tremendous swing upward. The stock is trading at $11.52 as of 10:17 a.m. ET, 23.2% above Tuesday's closing price of $9.35. Volume is at 309,301, 8.3 times the daily average of 37,100.

Derma Sciences: Drug Extends Wound Healing

Derma Sciences: Drug Extends Wound Healing

Derma intends to move experimental wound-healing drug into phase III studies following positive results from mid-stage study.

Derma Sciences Reports Continued Healing At 24 Weeks In Patients With Diabetic Foot Ulcers Treated With DSC127 In Phase 2 Trial

Derma Sciences Reports Continued Healing At 24 Weeks In Patients With Diabetic Foot Ulcers Treated With DSC127 In Phase 2 Trial

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced that in the follow-up portion of its Phase 2 clinical trial in patients with diabetic...

Derma Sciences To Hold Conference Call Tomorrow, May 25 To Discuss 24-Week Data From Phase 2 DSC127 Trial In Diabetic Foot Ulcers

Derma Sciences To Hold Conference Call Tomorrow, May 25 To Discuss 24-Week Data From Phase 2 DSC127 Trial In Diabetic Foot Ulcers

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, will issue a news release announcing 24-week data from its Phase 2 trial with DSC127 in diabetic foot...

Derma Sciences To Present At The Noble Financial Capital Markets’ Seventh Annual Equity Conference

Derma Sciences To Present At The Noble Financial Capital Markets’ Seventh Annual Equity Conference

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care announced today that the Company will be presenting at the Noble Financial Capital Markets’ Seventh ...

Derma Sciences First Quarter Results Feature Positive Cash Flow From Operations, Advanced Wound Care Product Sales Up 57%, Total Sales Up 12%

Derma Sciences First Quarter Results Feature Positive Cash Flow From Operations, Advanced Wound Care Product Sales Up 57%, Total Sales Up 12%

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three months ended March 31, 2011.

Derma Sciences To Hold First Quarter Financial Results Conference Call On May 11

Derma Sciences To Hold First Quarter Financial Results Conference Call On May 11

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care announced today that the Company will hold a conference call on May 11, 2011 to discuss the financial ...

Derma Sciences MEDIHONEY® And XTRASORB® Posters And Expert Presentations Featured At Symposium On Advanced Wound Care 2011

Derma Sciences MEDIHONEY® And XTRASORB® Posters And Expert Presentations Featured At Symposium On Advanced Wound Care 2011

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced that poster and expert presentations featuring MEDIHONEY ® and XTRASORB ®, two...

Derma Sciences Reports Fourth Quarter Results; Sales Of Advanced Wound Care Products Up 59% Over Prior Year; Total Net Sales New Record For Quarter

Derma Sciences Reports Fourth Quarter Results; Sales Of Advanced Wound Care Products Up 59% Over Prior Year; Total Net Sales New Record For Quarter

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three and 12 months ended December 31, 2010.

Derma Sciences Advanced Wound Care Products Featured In Five Poster Presentations At The Diabetic Foot Global Conference 2011

Derma Sciences Advanced Wound Care Products Featured In Five Poster Presentations At The Diabetic Foot Global Conference 2011

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced that five scientific abstracts based on commercial and development-stage products in the...

Derma Sciences Announces Fourth Quarter 2010 Financial Results Conference Call

Derma Sciences Announces Fourth Quarter 2010 Financial Results Conference Call

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care announced today that the Company will hold a conference call on March 30, 2011 to discuss the financial ...

5 Health Care Stocks With Upside

5 Health Care Stocks With Upside

These health care stocks are scheduled to report their quarterly earnings today.

Derma Sciences To Present At The Roth Capital Partners Growth Stock Conference

Derma Sciences To Present At The Roth Capital Partners Growth Stock Conference

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care announced today that the Company will be presenting at the ROTH Capital Partners 23rd Annual OC Growth ...

Derma Stock Gaps Up On Today's Open (DSCI)

Derma Stock Gaps Up On Today's Open (DSCI)

Shares of Derma (Nasdaq:DSCI) were gapping up Monday morning with an open price 11.7% higher than Friday's closing price. The stock closed at $10.29 yesterday and opened today's trading at $11.49.

Derma Sciences Receives FDA Clearance For MEDIHONEY® Gel

Derma Sciences Receives FDA Clearance For MEDIHONEY® Gel

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced receipt of 510(k) clearance from the U.

Department Of Health And Human Services Grants $4.5 Million To Research DSC127 in Skin Injuries Associated With Acute Radiation Exposure

Department Of Health And Human Services Grants $4.5 Million To Research DSC127 in Skin Injuries Associated With Acute Radiation Exposure

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced that researchers who invented DSC127 have been awarded a $4.

Derma Sciences To Present At The Lippert/Heilshorn Life Sciences & Medtech Virtual Conference On February 17

Derma Sciences To Present At The Lippert/Heilshorn Life Sciences & Medtech Virtual Conference On February 17

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced that Edward J.